Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Metso Outotec Corporation: Managers' transactions – Klaus Cawén

Metso Outotec Corporation’s stock exchange release on April 28, 2021, at 11:00 a.m. EESTMetso Outotec Corporation has received the following disclosure under EU Market Abuse Regulation No 596/2014, regarding managers' or their closely associated persons' transactions with Metso Outotec's shares. Person subjectto thenotificationrequirementName: Cawén, KlausPosition: Member of the Board InitialNotificationReference 549300R0VN9C371W0E07_20210427141157_201number: IssuerName: Metso Outotec CorporationLEI:

Metso Outotec Corporation: Managers' transactions – Kari Stadigh

Metso Outotec Corporation’s stock exchange release on April 28, 2021, at 11:00 a.m. EESTMetso Outotec Corporation has received the following disclosure under EU Market Abuse Regulation No 596/2014, regarding managers' or their closely associated persons' transactions with Metso Outotec's shares. Person subjectto thenotificationrequirementName: Stadigh, KariPosition: Member of the Board InitialNotificationReference 549300R0VN9C371W0E07_20210427141157_205number: IssuerName: Metso Outotec CorporationLEI:

Metso Outotec Corporation: Managers' transactions – Emanuela Speranza

Metso Outotec Corporation’s stock exchange release on April 28, 2021, at 11:00 a.m. EESTMetso Outotec Corporation has received the following disclosure under EU Market Abuse Regulation No 596/2014, regarding managers' or their closely associated persons' transactions with Metso Outotec's shares. Person subjectto thenotificationrequirementName: Speranza, EmanuelaPosition: Member of the Board InitialNotificationReference 549300R0VN9C371W0E07_20210427141157_206number: IssuerName: Metso Outotec CorporationLEI:

Metso Outotec Corporation: Managers' transactions – Christer Gardell

Metso Outotec Corporation’s stock exchange release on April 28, 2021, at 11:00 a.m. EESTMetso Outotec Corporation has received the following disclosure under EU Market Abuse Regulation No 596/2014, regarding managers' or their closely associated persons' transactions with Metso Outotec's shares. Person subjectto thenotificationrequirementName: Gardell, ChristerPosition: Member of the Board InitialNotificationReference 549300R0VN9C371W0E07_20210427141157_202number: IssuerName: Metso Outotec CorporationLEI:

Metso Outotec Corporation: Managers' transactions – Arja Talma

Metso Outotec Corporation’s stock exchange release on April 28, 2021, at 11:00 a.m. EESTMetso Outotec Corporation has received the following disclosure under EU Market Abuse Regulation No 596/2014, regarding managers' or their closely associated persons' transactions with Metso Outotec's shares. Person subjectto thenotificationrequirementName: Talma, ArjaPosition: Member of the Board InitialNotificationReference 549300R0VN9C371W0E07_20210427141157_207number: IssuerName: Metso Outotec CorporationLEI:

Metso Outotec Corporation: Managers' transactions – Antti Mäkinen

Metso Outotec Corporation’s stock exchange release on April 28, 2021, at 11:00 a.m. EESTMetso Outotec Corporation has received the following disclosure under EU Market Abuse Regulation No 596/2014, regarding managers' or their closely associated persons' transactions with Metso Outotec's shares. Person subjectto thenotificationrequirementName: Mäkinen, AnttiPosition: Member of the Board InitialNotificationReference 549300R0VN9C371W0E07_20210427141157_203number: IssuerName: Metso Outotec CorporationLEI:

FDA grants priority review for Nefecon, for patients with IgA nephropathy

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the U.S. Food and Drug Administration (FDA) has accepted the submission and granted Priority Review for the New Drug Application (NDA) for Nefecon, a down regulator of IgA1 for the treatment of IgA nephropathy (IgAN.) The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of September 15, 2021.“We are very excited about being granted priority review, which reflects the unmet medical need of IgAN. We look forward to engaging with the agency and work towards an accelerated

LDC is launched in the Nordics – delivering next-generation products for digital corporate communication

LDC, an independent company delivering innovative products and services for digital corporate communication, is today launched in the Nordics. Behind LDC are Fogel & Partners, the leading Nordic strategic communication advisor, and digital design, development and venturing partner, Levels Group.The landscape of corporate communication is rapidly changing, placing higher demands on companies to reach stakeholders. The idea behind LDC emerged from identifying the need for a new breed of efficient digital communication products, tools and solutions. By combining Fogel & Partners’ and Levels’

Share capital and total number of voting rights as at 28 April 2021

Vestas Wind Systems A/S, Aarhus, 28 April 2021Company announcement No. 09/2021  Vestas Wind Systems A/S has carried out a share split at a ratio of 1:5 with the record date 28 April 2021, cf. Company announcement no. 07/2021 of 8 April 2021. In accordance with section 32 of the Danish Capital Markets Act, Vestas Wind Systems A/S is required to disclose the total number of voting rights and the size of the share capital in the company no later than at the end of the month in which the changes have taken place. After the share split, Vestas Wind Systems A/S’ total share capital

Spago Nanomedical interim report January-March 2021

Successful rights issue strengthens project development JANUARY – MARCH IN BRIEF ·Net sales for the quarter amounted to KSEK 100 (KSEK 100). · The loss for the quarter amounted to KSEK -6,068 (KSEK -5,054). · Operating expenses for the quarter amounted to KSEK -7,439 (KSEK -6,769). · Earnings per share, before and after dilution, for the quarter amounted toSEK -0.18 (SEK -0.24). · Cash and cash equivalents at the end of the quarter amounted to KSEK 85,225 (KSEK 6 938). SIGNIFICANT EVENTS DURING THE QUARTER ·Spago Nanomedical was provided with MSEK 69 in an

Sari Pajari-Sederholm appointed Metsä Group’s EVP, Strategy

Metsä Group Stock Exchange Release, Changes in management, 28 April 2021 at 10 am EESTSari Pajari-Sederholm has been appointed Metsä Group’s EVP, Strategy as of 1 May 2021. She has worked within Metsä Group since 2007 e.g. as the Metsä Group’s CIO and in various management positions in the paperboard business, Metsä Board. Pajari-Sederholm moves to her new role from the position of Metsä Board’s SVP, Sales and Marketing. In her new position Pajari-Sederholm is responsible for the planning, preparation and implementation support of Metsä Group’s strategy, as well as various business

Wärtsilä and Tanger Med team up to co-develop next generation Port Management Information System

Wärtsilä Corporation, Press release, 28 April 2021 at 10 AM EESTWärtsilä has partnered with Tanger Med, the largest Mediterranean and African container port, to take a new step forward in global port efficiency by co-developing a new cutting-edge Port Management Information System (PMIS). Both organisations sealed their long-term commitment to deploy modern Smart Port tools for port operations and digitalisation – including implementing Just-In-Time (JIT) solutions, machine learning and AI as well as other innovative solutions.  This partnership positions Tanger Med and Wärtsilä as

Changes in Metsä Board Corporation’s Corporate Management Team

Metsä Board Corporation Stock Exchange Release Changes in management 28 April 2021 at 10 a.m. EESTJussi Noponen has been appointed SVP, Sales and Supply Chain at Metsä Board, part of Metsä Group. Noponen moves to his new role from the position of Metsä Board’s CFO, which he has held since 2016. Noponen has worked within Metsä Group in various mainly finance and control related positions since 2000. Sari Pajari-Sederholm, who has since 2017 held the position of Metsä Board’s SVP, Sales and Marketing, has been appointed Metsä Group’s EVP, Strategy. Henri Sederholm has been appointed Metsä

Securitas AB to publish the Interim report January-March 2021

Securitas AB will publish the Interim report for January-March 2021 on Wednesday, May 5, 2021, at approximately 1.00 p.m. (CET).App. 1.00 p.m. (CET) Report releaseThe report will be sent as a press release from Cision (www.cision.se) and will automatically be published on www.securitas.com when released. 2.00 p.m. (CET) Presentation slides available For presentation slides, follow the link www.securitas.com/presentations  3.00 p.m. (CET) Telephone conference and audio castAnalysts and media are invited to participate in a telephone conference at 3.00 p.m. (CET) where Securitas

Homepage About News Coop Norge selects Nagarro as strategic partner for SAP infrastructure and platform management services

Kronberg, 28. April 2021 – New partnership between Coop Norge SA and Nagarro ES (Enterprise Services): The grocery retailer and the IT full service provider signed a five-year contract for the delivery and operation of a new state-of-the-art infrastructure and technical platform for Coop’s business critical SAP landscape. After an initial transition phase, where Nagarro delivered and deployed the new infrastructure in Coop’s own Data Centres, the SAP landscape and its more than 80 systems have been migrated by the Nagarro team to a brand new and fully scalable platform. The migration

Interim report, January–March 2021

New CEO and new customer agreementsThe quarter January-March 2021 · Revenue amounted to TSEK 37,131 (59,576). · Operating profit amounted to TSEK -30,658 (5,355). · Profit after tax amounted to TSEK -11,254 (33,705). The result includes currency conversions costs of TSEK 19,399 (28,441). · Earnings per share amounted to -0.24 SEK (0.98). Significant events during the period · Ovzon certified according to ISO 9001. · Per Norén appointed new CEO takes office May 1, 2021. · Order from the Swedish defense supplier Saab regarding tests of the company’s satellite

Updated financial calendar for 2021

H+H International A/S (hereinafter referred to as “H+H” or “the Company”) hereby announces an update to the financial calendar for 2021. The planned publication of the Interim Financial Report covering the first three months of 2021 (“Q1 2021”) is changed to 12 May 2021 from previously 17 May 2021. H+H expects to publish its Q1 2021 Interim Financial Report in the early afternoon. H+H has thus scheduled the following dates for the remainder of 2021 for the release of financial reports: 12 May 2021 (early-afternoon) Interim Financial Report for Q1 202112 August 2021

Lumito AB Quarterly Report (1 Jan to 31 March) 2021

Significant events during the first quarter of 2021 ·Lumito’s advisors in the field of pathology have had the opportunity to review the company’s UCNP immunostaining of invasive breast cancer with an antibody against HER2 (the target molecule) at a high image resolution. “The signals are uniquely sharp and clear, which gives the impression of staining almost on the level of individual target molecules; in this sense, it is superior to any method currently in regular use in pathology laboratories,” says one of Lumito’s advisors, Björn L. Isfoss. ·An account was given of the

Interim Report, January – March 2021

PERIOD JANUARY 1 – MARCH 31, 2021 · Net sales of SEK 102 m (103 m) · Recurring revenues of SEK 66 m (61 m) · which corresponds to % of net sales 65 % (59 %) · EBITDA SEK 20 m (27 m) · EBITDA margin 19 % (26 %) · EBIT 6 m (15 m) · EBIT margin 6 % (14 %) · Net profit SEK 4 m (11 m) · Net profit margin 4 % (11 %) · EPS before dilution SEK 0.08 (0.21) · Cash flow from operating activities SEK 6 m (26 m) · ACV SEK 11 m (7 m) · ARR SEK 271 m (235 m) For the full report, see attached PDF.    For additional information, contact: Christian Sundin,

Transactions in connection with share buy-back programme

On 4 March 2021, H+H International A/S (hereinafter referred to as “H+H” or “the Company”) initiated a share buy-back programme in compliance with Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on Market Abuse and Commission Delegated Regulation (EU) 1052/2016 of 8 March 2016 (the “Safe Harbour Regulation”). On 18 March 2021, the share buy-back programme was increased by DKK 15 million, thereby increasing the maximum aggregate purchase price of the shares to be bought back under the programme to DKK 115 million. The share buy-back

The Nomination Committee's of Everysport Media Group AB (publ) proposals to the annual general meeting 2021

Everysport Media Goup AB (publ) today announces its Nomination Committee’s proposals to the annual general meeting 2021. Before the annual general meeting 2021, the Company's Nomination Committee has consisted of Paul Fischbein, in his capacity as Chairman of the Board of Directors of the Company and Johan Ejermark and Michael Hansen in their capacity as representatives of the two largest ownership groups/shareholders who have the largest shareholdings in the Company in terms of votes. Item 1 – Election of Chairman of the general meeting The Nomination Committee proposes that Paul

Atlas Copco’s Tensor ICB tool wins Red Dot Design Award

Nacka, Sweden, April 28, 2021: Atlas Copco has been awarded a prestigious Red Dot Design Award for 2021. The awarded Tensor ICB tool, part of the Tensor IxB tool family, increases efficiency, reduces the need for hardware and equipment, as well as reduces energy consumption.“We are proud to be recognized with this prize for outstanding design,” said Henrik Elmin, President of Atlas Copco’s Industrial Technique business area. “The Tensor IxB tools are designed to be ergonomic and provide customer benefits, but also to increase performance, efficiency and quality, and reduce the risk of human

Cereno Scientific signs agreement with University of Michigan to bring new preclinical candidate CS585 into clinical phase

Cereno Scientific today announced that a collaboration agreement for the full preclinical development program of the new drug candidate CS585 has been signed with the University of Michigan. The development agreement includes the successful transition of CS585 to a clinical Phase I program. The IND-enabling work will be conducted at the University of Michigan, a top-ranked public research university in the US with an extensive track record of successful collaborations with industry. CS585 is in development within cardiovascular diseases.“The preclinical development with CS585 will start

There are no items matching the current filter
There are no more items matching the current filter
Back to top